Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States.

Although statistically significant reductions in FL-related pharmacy costs (3L+, 4L+) and medical (4L+) costs were observed for CAR T compared with non-CAR T therapy in adjusted analyses ( Table 3 ), 3L+ medical costs did not reach statistical significance.

also in 111,027 other papers